Summary: More than two dozen mainstream media outlets are expanding psychedelic education by highlighting the research results from the first MAPS-sponsored Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), which follows the announcement published this week by The New York Times.
The Hill: Research Finds MDMA Can Help with PTSD
“Mental health experts told the [New York] Times that the study could lead to more studies on MDMA’s ability to treat other mental illnesses and on other psychedelics’ ability to treat other diseases.” —The Hill
Rolling Stone: Phase 3 Trial Shows Promising Results for MDMA-Assisted PTSD Therapy
“As is widely known, MDMA boosts serotonin, oxytocin, and dopamine to create feelings of euphoria, empathy, trust, and compassion; in a therapeutic context, it also seems capable of re-opening what neuroscientists call the “critical period” — a moment in childhood where the brain is capable of making and storing new memories.” —Rolling Stone
The Week Magazine: New Clinical Trial Boosts Case for Using MDMA to Treat Severe PTSD
“Mental health experts also expressed hope that this first Phase 3 trial on psychedelic-assisted therapy could pave the way for research on other banned psychedelics — including LSD, mescaline, and psilocybin (mushrooms) — or the use of MDMA on other intractable mental health conditions.” —The Week Magazine
Mic: MDMA-Assisted Therapy Will Be Here Soon, According to a New Study
“Assuming it happens, FDA approval of MDMA-assisted therapy for PTSD could free researchers to fully explore these substances’ potential for providing the relief that those who live with hard-to-treat mental illnesses need and deserve.” —Mic
Psychology Today: Psychedelics in Psychiatry: New Data Supporting an Old Idea
“This is an important study because it’s the largest study done to date, with results that—similar to previous smaller studies—are encouraging.” —Psychology Today
